http://www.shionogi.com/us/en/http://www.shionogi.com/us/en/about.htmlhttp://www.shionogi.com/us/en/about/philosophy.htmlhttp://www.shionogi.com/us/en/about/philosophy/code-of-conduct.htmlhttp://www.shionogi.com/us/en/about/philosophy/shionogi-group-philosophy.htmlhttp://www.shionogi.com/us/en/about/culture.htmlhttp://www.shionogi.com/us/en/about/transparency.htmlhttp://www.shionogi.com/us/en/about/transparency/compliance.htmlhttp://www.shionogi.com/us/en/about/transparency/ca-compliance.htmlhttp://www.shionogi.com/us/en/about/transparency/sunshine-act.htmlhttp://www.shionogi.com/us/en/about/transparency/supplier-diversity.htmlhttp://www.shionogi.com/us/en/about/leadership-team.htmlhttp://www.shionogi.com/us/en/about/leadership-team/tadashi-hara.htmlhttp://www.shionogi.com/us/en/about/leadership-team/nathan-mccutcheon.htmlhttp://www.shionogi.com/us/en/about/leadership-team/masahiro-fujita.htmlhttp://www.shionogi.com/us/en/about/leadership-team/margaret-borys.htmlhttp://www.shionogi.com/us/en/about/leadership-team/chris-klein.htmlhttp://www.shionogi.com/us/en/about/leadership-team/david-benadon.htmlhttp://www.shionogi.com/us/en/about/partners.htmlhttp://www.shionogi.com/us/en/about/partners/shionogi-and-hanavax-enter-into-a-license-agreement-for-covid-19-vaccine-development-using-cationic-nanogel-delivery-system.htmlhttp://www.shionogi.com/us/en/about/partners/shionogi-and-inveniaI-initiate-a-research-collaboration-agreement-aimed-for-ai-powered-multi-target-drug-discovery-collaboration.htmlhttp://www.shionogi.com/us/en/about/partners/virus-detection-method-of-viruses-and-bacteria-including-novel-coronavirus-between-hokkaido-university-and-shionogi.htmlhttp://www.shionogi.com/us/en/about/our-history.htmlhttp://www.shionogi.com/us/en/about/po-terms.htmlhttp://www.shionogi.com/us/en/innovation.htmlhttp://www.shionogi.com/us/en/innovation/investigator-research.htmlhttp://www.shionogi.com/us/en/innovation/clinical-trial-data-privacy-policy.htmlhttp://www.shionogi.com/us/en/innovation/pipeline.htmlhttp://www.shionogi.com/us/en/innovation/pipeline/global-pipeline.htmlhttp://www.shionogi.com/us/en/innovation/clinical-trial-data-transparency-policy.htmlhttp://www.shionogi.com/us/en/innovation/medical-information.htmlhttp://www.shionogi.com/us/en/innovation/medical-information/submit-a-medical-inquiry.htmlhttp://www.shionogi.com/us/en/innovation/medical-information/request-a-medical-science-liaison.htmlhttp://www.shionogi.com/us/en/innovation/developing-innovative-therapies-to-address-unmet-needs.htmlhttp://www.shionogi.com/us/en/innovation/expanded-access-policy.htmlhttp://www.shionogi.com/us/en/innovation/expanded-access-policy/ensitrelvir-expanded-access.htmlhttp://www.shionogi.com/us/en/innovation/clinical-trials.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials/experience-204-adolescent-males-study.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials/experience-301-adult-males-study.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials/experience-302-open-label-extension-study.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials/what-to-expect-during-your-visits.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials/welcome-to-shionogi.htmlhttp://www.shionogi.com/us/en/innovation/fragile-x-syndrome-clinical-trials/enrollment-update.htmlhttp://www.shionogi.com/us/en/innovation/rare-disease-patient-advocacy.htmlhttp://www.shionogi.com/us/en/news.htmlhttp://www.shionogi.com/us/en/news/2022.htmlhttp://www.shionogi.com/us/en/news/2022/02.htmlhttp://www.shionogi.com/us/en/news/2022/02/shionogi-presents-phase-2-3-clinical-trial-results-for-the-COVID-19-therapeutic-drug-S-217622.htmlhttp://www.shionogi.com/us/en/news/2022/02/shionogi-files-for-approval-of-s-217622-a-therapeutic-drug-for-covid-19-in-japan.htmlhttp://www.shionogi.com/us/en/news/2022/03.htmlhttp://www.shionogi.com/us/en/news/2022/03/shionogi-provides-humanitarian-aid-to-ukraine.htmlhttp://www.shionogi.com/us/en/news/2022/03/actg-and-shionogi-announce-progress-on-global-phase-3-trial-of-novel-covid-19-oral-antiviral-agent-s-217622.htmlhttp://www.shionogi.com/us/en/news/2022/04/new-data-for-shionogis-covid-19-once-daily-oral-antiviral-s-217622-show-rapid-virus-clearance.htmlhttp://www.shionogi.com/us/en/news/2022/06.htmlhttp://www.shionogi.com/us/en/news/2022/06/shionogi-announces-strategic-re-organization-of-us-executive-leadership.htmlhttp://www.shionogi.com/us/en/news/2022/06/shionogi-gardp-and-chai-announce-landmark-license-and-collaboration-agreements-to-treat-bacterial-infections-by-expanding-access-to-cefiderocol-in-135-countries.htmlhttp://www.shionogi.com/us/en/news/2022/07.htmlhttp://www.shionogi.com/us/en/news/2022/07/notice-regarding-the-launch-of-the-new-shionogi-group-brand.htmlhttp://www.shionogi.com/us/en/news/2022/07/s-217622-a-therapeutic-drug-for-covid-19-shows-high-in-vitro-antiviral-activity-against-omicron-subvariants-ba4-and-ba5.htmlhttp://www.shionogi.com/us/en/news/2022/08.htmlhttp://www.shionogi.com/us/en/news/2022/08/ensitrelvir-fumaric-acid-s-217622-a-therapeutic-drug-for-covid-19-shows-high-in-vitro-antiviral-activity-against-omicron-subvariants-bs-2-75.htmlhttp://www.shionogi.com/us/en/news/2022/09/shionogi-announces-achievement-of-the-primary-endpoint-for-ensitrelvir-fumaric-acid-s-217622-in-the-phase-3-part-of-the-phase-2-3-clinical-trial-in-asia.htmlhttp://www.shionogi.com/us/en/news/2022/10.htmlhttp://www.shionogi.com/us/en/news/2022/10/shionogi-and-the-medicines-patent-pool-mpp-sign-licence-agreement-for-covid-19-oral-antiviral-treatment-candidate-to-increase-access-in-low-and-middle-income-countries.htmlhttp://www.shionogi.com/us/en/news/2022/10/shionogi-presents-real-world-evidence-showing-strong-efficacy-with-fetroja-cefiderocol-against-treatment-resistant-bacterial-infections-at-idweek-2022.htmlhttp://www.shionogi.com/us/en/news/2022/11.htmlhttp://www.shionogi.com/us/en/news/2022/11/xocova-ensitrelvir-fumaric-acid-tablets-125mg-approved-in-japan-for-the-treatment-of-sars-cov-2-infection,-under-the-emergency-regulatory-approval-system.htmlhttp://www.shionogi.com/us/en/news/2020/2/shionogis-fetroja-cefiderocol-now-available-for-the-treatment-of-complicated-urinary-tract-infections-in-the-u-s.htmlhttp://www.shionogi.com/us/en/news/2020/4/shionogi-accelerates-development-of-potential-covid-19-treatments-and-vaccine.htmlhttp://www.shionogi.com/us/en/news/2020/6/FDA-Accepts-Shionogis-Supplemental-New-Drug-Application-with-Priority-Review-for-FETROJA.htmlhttp://www.shionogi.com/us/en/news/2020/8.htmlhttp://www.shionogi.com/us/en/news/2020/8/New-AMR-Action-Fund-steps-in-to-save-collapsing-antibiotic-pipeline-with-pharmaceutical-industry-investment-of-USD-1-billion.htmlhttp://www.shionogi.com/us/en/news/2020/9/shionogi-granted-new-technology-add-on-payment-for-fetroja-cefiderocol-by-cms.htmlhttp://www.shionogi.com/us/en/news/2020/9/shionogi-announces-fda-approval-of-fetroja-cefiderocol-for-the-treatment-of-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia.htmlhttp://www.shionogi.com/us/en/news/2020/10.htmlhttp://www.shionogi.com/us/en/news/2020/10/Shionogi-Announces-Publication-of-a-New-Systematic-Review-in-Chest-Highlighting-the-Importance-of-Early-Appropriate-Therapy-To-Improve-Meaningful-Outcomes-Like-Mortality-in-Patients-With-Severe-Bacterial-Infections.htmlhttp://www.shionogi.com/us/en/news/2020/10/shionogi-announces-publication-of-two-studies-in-the-lancet-infectious-diseases-highlighting-the-efficacy-and-safety-of-fetroja-cefiderocol-for-the-treatment-of-infections-due-to-aerobic-gram-negative-bacteria-in-adults-with-limited-treatment-options.htmlhttp://www.shionogi.com/us/en/news/2020/10/Shionogi-To-Present-New-Data-on-Fetroja-Cefiderocol-at-Idweek-2020.htmlhttp://www.shionogi.com/us/en/news/2021/5/shionogi-strengthens-us-executive-leadership-team-to-support-growth.htmlhttp://www.shionogi.com/us/en/news/2021/7/shionogi-announces-in-vitro-and-real-world-data-presented-at-eccmid-2021-demonstrating-activity-of-fetroja-cefiderocol-against-critical-priority-gram-negative-bacterial-pathogens.htmlhttp://www.shionogi.com/us/en/news/2021/9.htmlhttp://www.shionogi.com/us/en/news/2021/9/shionogi-to-present-in-vitro-and-real-world-data-at-idweek-2021-demonstrating-activity-of-fetroja-cefiderocol-against-gram-negative-pathogens.htmlhttp://www.shionogi.com/us/en/news/2021/10/shionogi-presents-the-results-of-covid-19-therapeutic-agent-at-isirv-who-virtual-conference.htmlhttp://www.shionogi.com/us/en/news/2023.htmlhttp://www.shionogi.com/us/en/news/2023/02.htmlhttp://www.shionogi.com/us/en/news/2023/02/shionogi-advances-ensitrelvir-fumaric-acid-covid-19-antiviral-clinical-program.htmlhttp://www.shionogi.com/us/en/news/2023/02/shionogi-presents-pivotal-ensitrelvir-fumaric-acid-phase-3-data-and-exploratory-long-covid-data-at-croi.htmlhttp://www.shionogi.com/us/en/news/2023/04.htmlhttp://www.shionogi.com/us/en/news/2023/04/shionogi-receives-us-fda-fast-track-designation-for-ensitrelvir-fumaric-acid-an-investigational-oral-antiviral-for-covid-19.htmlhttp://www.shionogi.com/us/en/news/2023/04/eccmid-2023-shionogi-to-present-data-showing-covid-19-symptom-recurrence-is-not-associated-with-ensitrelvir-treatment.htmlhttp://www.shionogi.com/us/en/news/2023/04/shionogi-and-co-ltd-announces-initiation-of-a-global-late-phase-2-clinical-trial-of-investigational-redasemtide-in-patients-with-acute-ischemic-stroke.htmlhttp://www.shionogi.com/us/en/news/2023/04/eccmid-2023-shionogi-announces-real-world-evidence-demonstrating-the-efficacy-of-fetcroja-fetroja-cefiderocol-against-some-of-the-most-difficult-to-treat-gram-negative-bacterial-pathogens.htmlhttp://www.shionogi.com/us/en/news/2023/05.htmlhttp://www.shionogi.com/us/en/news/2023/05/shionogi-expands-its-covid-19-product-portfolio-by-initiating-a-phase-1-clinical-trial-in-japan-for-a-second-covid-19-antiviral.htmlhttp://www.shionogi.com/us/en/news/2023/05/shionogi-inc-announces-christopher-klein-as-senior-vice-president-general-counsel.htmlhttp://www.shionogi.com/us/en/news/2023/06.htmlhttp://www.shionogi.com/us/en/news/2023/06/shionogi-enrolls-the-first-participant-in-japan-in-its-global-phase-3-trial-of-ensitrelvir-for-the-prevention-of-symptomatic-sars-cov-2-infection.htmlhttp://www.shionogi.com/us/en/news/2023/06/shionogi-further-extends-infectious-disease-innovation-platform-with-planned-acquisition-of-qpex-biopharma-inc.htmlhttp://www.shionogi.com/us/en/news/2023/09.htmlhttp://www.shionogi.com/us/en/news/2023/09/idweek-2023-shionogi-and-qpex-biopharma-inc-continue-longstanding-commitment-to-addressing-unmet-needs-in-infectious-disease.htmlhttp://www.shionogi.com/us/en/news/2023/09/critical-agreement-paves-way-for-new-model-to-accelerate-access-to-important-antibiotics-for-serious-bacterial-infections.htmlhttp://www.shionogi.com/us/en/news/2023/09/shionogi-presents-new-ensitrelvir-clinical-and-real-world-data-reinforcing-potential-across-covid-19-populations-at-eswi-2023.htmlhttp://www.shionogi.com/us/en/news/2023/09/zatolmilast-an-investigational-treatment-for-fragile-x-syndrome-receives-rare-pediatric-disease-designation-from-the-us-fda.htmlhttp://www.shionogi.com/us/en/news/2023/10.htmlhttp://www.shionogi.com/us/en/news/2023/10/shionogi-presents-new-ensitrelvir-covid-19-data-supporting-effectiveness-in-real-world-and-clinical-settings-at-idweek-2023.htmlhttp://www.shionogi.com/us/en/news/2023/10/idweek-2023-shionogi-presents-new-real-world-evidence-demonstrating-effectiveness-of-earlier-treatment-with-fetroja-cefiderocol-in-appropriate-patients.htmlhttp://www.shionogi.com/us/en/news/2023/11.htmlhttp://www.shionogi.com/us/en/news/2023/11/establishment-of-a-joint-venture-company-with-apnimed-for-solving-challenges-in-sleep-disorders.htmlhttp://www.shionogi.com/us/en/news/social-media-community-guidelines.htmlhttp://www.shionogi.com/us/en/news/2024.htmlhttp://www.shionogi.com/us/en/news/2024/02.htmlhttp://www.shionogi.com/us/en/news/2024/02/shionogi-strengthens-regulatory-leadership-with-the-appointment-of-dr-ramon-polo-as-senior-vice-president-head-of-regulatory-affairs.htmlhttp://www.shionogi.com/us/en/news/2024/02/shionogi-announces-new-phase-3-data-showing-early-resolution-of-many-common-covid-19-symptoms-in-jama-network-open.htmlhttp://www.shionogi.com/us/en/news/2024/03.htmlhttp://www.shionogi.com/us/en/news/2024/03/shionogi-announces-xocova-ensitrelvir-fumaric-acid-obtained-standard-approval-in-japan-for-the-treatment-of-sars-cov-2-infection.htmlhttp://www.shionogi.com/us/en/news/2024/04/escmid-global-2024-shionogi-presents-real-world-data-demonstrating-efficacy-of-fetcroja-fetroja-cefiderocol-in-critically-ill-patients-with-certain-difficult-to-treat-bacterial-infections.htmlhttp://www.shionogi.com/us/en/news/2024/05.htmlhttp://www.shionogi.com/us/en/news/2024/05/shionogi-provides-updates-from-scorpio-hr,-a-global-phase-3-study-of-ensitrelvir-for-non-hospitalized-participants-with-covid-19.htmlhttp://www.shionogi.com/us/en/news/2024/05/Shionogi-Co-Ltd-and-Maze-Therapeutics-Inc-Announce-Exclusive-Worldwide-License-Agreement-for-MZE001-a-Novel-Therapeutic-Candidate-for-the-Treatment-of-Pompe-Disease.htmlhttp://www.shionogi.com/us/en/news/2024/06.htmlhttp://www.shionogi.com/us/en/news/2024/06/shionogi-expands-global-infectious-disease-and-antimicrobial-research-operations-to-us-to-address-current-and-emerging-health-threats.htmlhttp://www.shionogi.com/us/en/news/2024/06/shionogi-inc-appoints-david-benadon-senior-vice-president-chief-human-resources-officer.htmlhttp://www.shionogi.com/us/en/news/2024/07.htmlhttp://www.shionogi.com/us/en/news/2024/07/shionogi-provides-updates-on-zatolmilast-an-investigational-drug-for-fragile-x-syndrome-including-recent-changes-to-study-protocol-to-increase-access-for-participants-and-families.htmlhttp://www.shionogi.com/us/en/news/2024/09.htmlhttp://www.shionogi.com/us/en/news/2024/09/shionogi-continues-global-commitment-to-advances-in-infectious-disease-with-key-data-presentations-from-its-expanding-product-portfolio-at-idweek-2024.htmlhttp://www.shionogi.com/us/en/news/2024/10.htmlhttp://www.shionogi.com/us/en/news/2024/10/idweek-2024-shionogi-presents-largest-global-real-world-evidence-study-of-cefiderocol-demonstrating-strong-clinical-response-rates-across-seriously-ill-patients.htmlhttp://www.shionogi.com/us/en/news/2024/10/receives-us-fda-fast-track-designation-for-the-novel-anti-respiratory-syncytial-virus-drug-candidate-s-337395.htmlhttp://www.shionogi.com/us/en/news/2024/10/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of-ensitrelvir-prevents-symptomatic-covid-19.htmlhttp://www.shionogi.com/us/en/news/2025.htmlhttp://www.shionogi.com/us/en/news/2025/01.htmlhttp://www.shionogi.com/us/en/news/2025/01/shionogi-receives-award-through-bardas-rapid-response-partnership-vehicle-to-advance-long-acting-formulation-of-s-892216-an-antiviral-for-covid-19-pre-exposure-prophylaxis-in-at-risk-populations.htmlhttp://www.shionogi.com/us/en/news/2025/01/shionogi-announces-positive-results-from-phase-2-trial-of-respiratory-syncytial-virus-oral-antiviral-candidate-s-337395.htmlhttp://www.shionogi.com/us/en/news/2025/02.htmlhttp://www.shionogi.com/us/en/news/2025/02/shionogi-and-jordans-guardian-angels-announce-first-ever-human-drug-study-for-jordans-syndrome-an-ultra-rare-genetic-neurodevelopmental-disorder.htmlhttp://www.shionogi.com/us/en/news/2025/02/approval-for-fetroja-cefiderocol-in-south-korea.htmlhttp://www.shionogi.com/us/en/news/2025/03.htmlhttp://www.shionogi.com/us/en/news/2025/03/late-breaking-at-croi-2025-scorpio-pep-phase-3-trial-ensitrelvir-is-the-first-and-only-covid-19-oral-antiviral-to-demonstrate-prevention-of-covid-19-as-post-exposure-prophylaxis.htmlhttp://www.shionogi.com/us/en/news/2025/04.htmlhttp://www.shionogi.com/us/en/news/2025/04/shionogi-initiates-new-drug-application-submission-for-ensitrelvir-for-post-exposure-prophylaxis-with-the-us-food-and-drug-administration.htmlhttp://www.shionogi.com/us/en/news/2025/04/escmid-global-2025.htmlhttp://www.shionogi.com/us/en/news/2025/05.htmlhttp://www.shionogi.com/us/en/news/2025/05/announcement-of-agreement-on-company-split-simplified-absorption-type-split-of-japan-tobacco-incs-pharmaceutical-business-and-acquisition-of-shares-of-akros-pharma-inc-by-shionogi-inc-making-it-a-subsidiary.htmlhttp://www.shionogi.com/us/en/news/2025/09.htmlhttp://www.shionogi.com/us/en/news/2025/09/fda-accepts-shionogis-ensitrelvir-nda-as-the-first-oral-therapy-for-the-prevention-of-covid-19-following-exposure.htmlhttp://www.shionogi.com/us/en/news/2025/09/shionogi-to-present-new-data-from-anti-infective-portfolio-at-idweek.htmlhttp://www.shionogi.com/us/en/news/2025/10.htmlhttp://www.shionogi.com/us/en/news/2025/10/idweek-2025-shionogi-presents-real-world-and-surveillance-data-reinforcing-role-of-cefiderocol-across-range-of-patient-populations-and-difficult-to-treat-infections.htmlhttp://www.shionogi.com/us/en/news/2025/12.htmlhttp://www.shionogi.com/us/en/news/2025/12/notice-regarding-completion-of-succession-of-japan-tobacco-incs-pharmaceutical-business-through-simplified-absorption-type-company-split.htmlhttp://www.shionogi.com/us/en/news/2025/12/shionogi-inc-appoints-ann-howell-pharmd-ms-as-senior-vice-president-global-head-of-regulatory-affairs.htmlhttp://www.shionogi.com/us/en/news/2025/12/shionogi-expands-rare-disease-presence-with-planned-acquisition-of-global-rights-to-tanabe-pharma-corporations-radicava-ors-edaravone-and-iv-radicava.htmlhttp://www.shionogi.com/us/en/news/2025/12/announcement-of-the-conclusion-of-a-joint-research-development-agreement-and-investment-agreement-with-salubritas-therapeutics.htmlhttp://www.shionogi.com/us/en/news/2026.htmlhttp://www.shionogi.com/us/en/news/2026/03.htmlhttp://www.shionogi.com/us/en/news/2026/03/shionogi-announces-first-patients-enrolled-in-global-phase-2-clinical-trial-in-adults-with-late-onset-pompe-disease.htmlhttp://www.shionogi.com/us/en/products.htmlhttp://www.shionogi.com/us/en/careers.htmlhttp://www.shionogi.com/us/en/careers/meet-our-people1.htmlhttp://www.shionogi.com/us/en/careers/benefits.htmlhttp://www.shionogi.com/us/en/contact.htmlhttp://www.shionogi.com/us/en/privacy-policy.htmlhttp://www.shionogi.com/us/en/privacy-policy/ccpa-privacy-policy-and-notice.htmlhttp://www.shionogi.com/us/en/privacy-policy/data-privacy-framework-policy.htmlhttp://www.shionogi.com/us/en/shionogi-inc-terms-of-use.htmlhttp://www.shionogi.com/us/en/sustainability.htmlhttp://www.shionogi.com/us/en/sustainability/shionogi-group-sustainability.htmlhttp://www.shionogi.com/us/en/sustainability/shionogi-and-the-medicines-patent-pool-mpp-sign-licence-agreement-for-covid-19-oral-antiviral-treatment-candidate-to-increase-access-in-low--and-middle-income-countries.htmlhttp://www.shionogi.com/us/en/sustainability/environment.htmlhttp://www.shionogi.com/us/en/sustainability/address-the-problem-of-antimicrobial-resistance-AMR.htmlhttp://www.shionogi.com/us/en/sustainability/shionogi-group-ehs-code-of-conduct.htmlhttp://www.shionogi.com/us/en/sustainability/respect-human-rights.htmlhttp://www.shionogi.com/us/en/investors.htmlhttp://www.shionogi.com/us/en/worldwide.html